Evusheld is an FDA authorized preventative monoclonal antibody treatment for pre-exposure prophylaxis of COVID-19 for immunocompromised adults and pediatric patients (12 years of age and older weighing at least 40 kg):
Who is NOT currently infected with SARS-CoV-2 and has NOT had a known recent exposure to an individual infected with SARS-CoV-2, or
Who is moderately to severely immunocompromised due to a medical condition, or receipt of immunosuppressive medications or treatments, and may not mount an adequate immune response to COVID-19 vaccinations, or
Where vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).
TREATMENT – WHAT TO EXPECT
Evusheld is given as 2 separate, consecutive intramuscular injections of tixagevimab and cilgavimab. Patient will be observed for 1 hour after administration.